• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Teva Pharmaceutical Industries Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    5/28/25 4:11:41 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TEVA alert in real time by email
    8-K
    TEVA PHARMACEUTICAL INDUSTRIES LTD 00-0000000 false 0000818686 0000818686 2025-05-28 2025-05-28
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported) May 28, 2025

     

     

    TEVA PHARMACEUTICAL INDUSTRIES LIMITED

    (Exact name of registrant as specified in its charter)

     

     

     

    Israel   001-16174   Not Applicable

    (State or other jurisdiction of

    incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    124 Dvora HaNevi’a Street

    Tel Aviv 6944020, Israel

    (Address of principal executive offices) (Zip Code)

    +972-3-914-8213

    (Registrant’s telephone number, including area code)

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    American Depositary Shares, each representing one Ordinary Share   TEVA   New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ((§240.12b-2 of this chapter).

    Emerging Growth Company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 1.01.

    Entry into a Material Definitive Agreement.

    On May 28, 2025, (i) Teva Pharmaceutical Finance Netherlands II B.V. (“Teva Finance II”), a wholly owned subsidiary of Teva Pharmaceutical Industries Limited (the “Company”), issued €1,000,000,000 aggregate principal amount of 4.125% Senior Notes due 2031 (the “Euro Notes”); (ii) Teva Pharmaceutical Finance Netherlands III B.V. (“Teva Finance III”), a wholly owned subsidiary of the Company, issued $500,000,000 aggregate principal amount of 6.000% Senior Notes due 2032 (the “2032 USD Notes”); and (iii) Teva Pharmaceutical Finance Netherlands IV B.V. (“Teva Finance IV” and, together with Teva Finance II and Teva Finance III, the “Issuers”), a wholly owned subsidiary of the Company, issued $700,000,0000 aggregate principal amount of 5.750% Senior Notes due 2030 (the “2030 USD Notes” and, together with 2030 USD Notes, the “USD Notes” and together with the Euro Notes, the “Notes”).

    Teva intends to use the net proceeds from the Notes (i) to fund the announced tender offer for a maximum combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $2,250,000,000 (equivalent) (upsized from a previously announced cap of $2,000,000,000), (ii) to pay fees and expenses in connection therewith, and (iii) to the extent of any remaining proceeds, for the repayment of outstanding debt upon maturity, tender offer or earlier redemption. Net proceeds may be temporarily invested pending application for their stated purpose.

    The Euro Notes were issued pursuant to a Senior Indenture, dated as of March 14, 2018 (the “Euro Notes Base Indenture”), by and among Teva Finance II, the Company, as guarantor, and The Bank of New York Mellon, as trustee, as supplemented by the Fifth Supplemental Indenture, dated as of May 28, 2025 (the “Euro Notes Supplemental Indenture” and, together with the Euro Notes Base Indenture, the “Euro Notes Indenture”), by and among Teva Finance II, the Company, as guarantor, The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, London Branch, as paying agent. The 2032 USD Notes were issued pursuant to a Senior Indenture, dated as of March 14, 2018 (the “2032 USD Notes Base Indenture”), as supplemented by the Fifth Supplemental Indenture, dated as of May 28, 2025 (the “2032 USD Notes Supplemental Indenture” and, together with the 2032 USD Notes Base Indenture, the “2032 USD Notes Indenture”), in each case, by and among Teva Finance III, the Company, as guarantor, and The Bank of New York Mellon, as trustee. The 2030 USD Notes were issued pursuant to a Senior Indenture, dated as of May 28, 2025 (the “2030 USD Notes Base Indenture”), as supplemented by the First Supplemental Indenture, dated as of May 28, 2025 (the “2030 USD Notes Supplemental Indenture” and, together with the 2030 USD Notes Base Indenture, the “2030 USD Notes Indenture” and, together with the Euro Notes Indenture and the 2032 USD Notes Indenture, the “Indentures”), in each case, by and among Teva Finance IV, the Company, as guarantor, and The Bank of New York Mellon, as trustee.

    Interest will be payable on the Euro Notes annually in arrears on June 1 of each year, beginning on June 1, 2026, until their maturity date of June 1, 2031. Interest will be payable on the USD notes semi-annually in arrears on June 1 and December 1 of each year, beginning on December 1, 2025, until their maturity dates of December 1, 2032 for the 2032 USD Notes and December 1, 2030 for the 2030 USD Notes. The Euro Notes and the USD Notes are senior unsecured obligations of Teva Finance II, and Teva Finance III and Teva Finance IV, respectively, and the Notes are guaranteed on a senior unsecured basis by the Company.

    Teva Finance II may redeem the Euro Notes, in whole or in part, at any time or from time to time, upon at least 10 days’, but not more than 60 days’, prior notice delivered to the registered address of each holder of the Euro Notes to be redeemed with a copy of such notice delivered to the trustee and the paying agent. The Euro Notes will be redeemable at a redemption price equal to the greater of (1) 100% of the principal amount of the Euro Notes to be redeemed or (2) the sum of the present values of the Remaining Scheduled Payments (as defined in the Euro Notes Indenture) of the Euro Notes being redeemed discounted, on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months), at the applicable Reinvestment Rate (as defined in the Euro Notes Indenture), plus accrued and unpaid interest thereon, if any to, but not including, the redemption date; provided that if Teva Finance II elects to redeem the Euro Notes at any time on or after March 1, 2031 (three months prior to the maturity date of the Euro Notes), Teva Finance II may redeem the such Euro Notes, in whole or in part, at a redemption price equal to 100% of the principal amount of the Euro Notes then outstanding to be redeemed, plus accrued and unpaid interest thereon, if any, to, but not including, the redemption date.


    Teva Finance III and Teva Finance IV may redeem the 2032 USD Notes and the 2030 USD Notes, respectively, in whole or in part, at any time or from time to time, upon at least 10 days’, but not more than 60 days’, prior notice. The USD Notes will be redeemable at a redemption price equal to the greater of (1) 100% of the principal amount of the USD Notes to be redeemed or (2) the sum of the present values of the Remaining Scheduled Payments (as defined in the 2032 USD Notes Indenture and 2030 USD Notes Indenture, respectively) of the USD Notes of such series being redeemed discounted, on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months), using a discount rate equal to the sum of the Treasury Rate (as defined in the 2032 USD Notes Indenture and 2030 USD Notes Indenture, respectively) plus 50 basis points, plus in each case accrued and unpaid interest thereon, if any, to, but not including, the redemption date; provided that if Teva Finance III elects to redeem the 2032 USD Notes at any time on or after September 1, 2032 (three months prior to the maturity date of the 2032 USD Notes) or if Teva Finance IV elects to redeem the 2030 USD Notes at any time on or after September 1, 2030 (three months prior to the maturity date of the 2030 USD Notes), Teva Finance III or Teva Finance IV, as applicable, may redeem the USD Notes, in whole or in part, at a redemption price equal to 100% of the principal amount of such series of USD Notes then outstanding to be redeemed, plus accrued and unpaid interest thereon, if any, to, but not including, the redemption date.

    The terms of the Indentures, among other things and subject to specified exceptions, limit the ability of (a) the Company and its subsidiaries to (i) create liens upon certain of their property and (ii) enter into sale-leaseback transactions; and (b) the applicable Issuer and the Company to merge, consolidate or sell, lease or convey all or substantially all of their assets. The Indentures provide for customary events of default, which include (subject in certain cases to customary grace and cure periods), among others, nonpayment of principal or interest; breach of other covenants or agreements in the Indentures; acceleration of certain other indebtedness; failure of the Company’s guarantee to be enforceable; and certain events of bankruptcy or insolvency. The offering of the Notes was registered under the Securities Act of 1933, as amended (the “Securities Act”), and is being made pursuant to the Company’s Registration Statement on Form S-3ASR (File No. 333-284770) and the prospectus included therein (the “Registration Statement”), filed by the Company with the Commission on February 7, 2025, the preliminary prospectus supplement relating thereto, dated May 19, 2025, and filed with the Commission on May 19, 2025 pursuant to Rule 424(b)(3) promulgated under the Securities Act and the free writing prospectus related thereto, dated May 20, 2025, and filed with the Commission on May 20, 2025 pursuant to Rule 433 under the Securities Act.

    The foregoing summary descriptions of the Euro Notes Base Indenture, Euro Notes Supplemental Indenture, 2032 USD Notes Base Indenture, 2032 USD Notes Supplemental Indenture, 2030 USD Notes Base Indenture, 2032 USD Notes Supplemental Indenture and each series of Notes are not complete and are qualified in their entirety by reference to the Euro Notes Base Indenture, the Euro Notes Supplemental Indenture, the form of 2031 Euro Notes, the 2032 USD Notes Base Indenture, the 2032 USD Notes Supplemental Indenture, the form of 2032 USD Notes, the 2030 USD Notes Base Indenture, the 2030 USD Notes Supplemental Indenture and the form of 2030 USD Notes, which are filed as Exhibits 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8 and 4.9, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

     

    Item 2.03

    Creation of a Direct Financial Obligation or an Obligation under an Off Balance Sheet Arrangement of a Registrant.

    The information set forth in Item 1.01 is incorporated by reference into this Item 2.03.

     

    3


    Item 9.01

    Financial Statements and Exhibits

    (d) Exhibits

     

    Exhibit     
    4.1*    Senior Indenture, dated as of March 14, 2018, among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee (incorporated by reference to Exhibit 4.30 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed by the registrant on February 19, 2019).
    4.2    Fifth Supplemental Senior Indenture, dated as of May 28, 2025, among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited, The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, London Branch, as paying agent.
    4.3    Form of 2031 Euro Notes (included in Exhibit 4.2).
    4.4*    Senior Indenture, dated as of March 14, 2018, among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee (incorporated by reference to Exhibit 4.27 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed by the registrant on February 19, 2019).
    4.5    Fifth Supplemental Senior Indenture, dated as of May 28, 2025, among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee.
    4.6    Form of 2032 USD Notes (included in Exhibit 4.5).
    4.7    Senior Indenture, dated as of May 28, 2025, among Teva Pharmaceutical Finance Netherlands IV B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee.
    4.8    First Supplemental Senior Indenture, dated as of May 28, 2025, among Teva Pharmaceutical Finance Netherlands IV B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee.
    4.9    Form of 2030 USD Notes (included in Exhibit 4.8).
    5.1    Opinion of Agmon with Tulchinsky Law Firm (Israeli law)
    5.2    Opinion of Kirkland & Ellis LLP (New York law)
    5.3    Opinion of Van Doorne N.V. (Dutch law)
    23.1    Consent of Agmon with Tulchinsky Law Firm (included in Exhibit 5.1)
    23.2    Consent of Kirkland & Ellis LLP (included in Exhibit 5.2)
    23.3    Consent of Van Doorne N.V. (included in Exhibit 5.3)
    104    Cover Page Interactive Data File (included within the Inline XBRL document).

     

    *

    Previously Filed

     

    4


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: May 28, 2025

     

    TEVA PHARMACEUTICAL INDUSTRIES LIMITED
    By:  

    /s/ Eli Kalif

    Name:   Eli Kalif
    Title:   Executive Vice President, Chief Financial Officer

     

    5

    Get the next $TEVA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TEVA

    DatePrice TargetRatingAnalyst
    6/6/2025$24.00Buy
    Goldman
    5/28/2025$25.00Buy
    Truist
    5/12/2025$23.00Neutral → Overweight
    Analyst
    7/10/2024$20.00Hold → Buy
    Argus
    3/8/2024$14.00Underweight → Neutral
    JP Morgan
    2/12/2024$12.00 → $19.00Neutral → Overweight
    Piper Sandler
    1/23/2024$10.00 → $14.00Hold → Buy
    Jefferies
    1/3/2024$8.00 → $12.00Underweight → Neutral
    Piper Sandler
    More analyst ratings

    $TEVA
    SEC Filings

    See more
    • SEC Form 8-K filed by Teva Pharmaceutical Industries Limited

      8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)

      6/5/25 4:52:32 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by Teva Pharmaceutical Industries Limited

      SD - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)

      6/2/25 4:06:38 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva Pharmaceutical Industries Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

      8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)

      5/28/25 4:11:41 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Financial Officer Kalif Eliyahu Sharon sold $952,464 worth of Ordinary Shares (55,775 units at $17.08), decreasing direct ownership by 12% to 403,288 units (SEC Form 4)

      4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

      6/16/25 4:03:30 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Vergis Janet S. converted options into 9,632 units of Ordinary Shares, increasing direct ownership by 15% to 73,697 units (SEC Form 4)

      4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

      6/9/25 4:25:12 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Zaks Tal Zvi converted options into 9,632 units of Ordinary Shares, increasing direct ownership by 20% to 58,772 units (SEC Form 4)

      4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

      6/9/25 4:22:54 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Teva Pharma with a new price target

      Goldman initiated coverage of Teva Pharma with a rating of Buy and set a new price target of $24.00

      6/6/25 8:33:51 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Truist initiated coverage on Teva Pharma with a new price target

      Truist initiated coverage of Teva Pharma with a rating of Buy and set a new price target of $25.00

      5/28/25 9:09:46 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva Pharma upgraded by Analyst with a new price target

      Analyst upgraded Teva Pharma from Neutral to Overweight and set a new price target of $23.00

      5/12/25 8:18:58 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Teva Releases Q2 2025 Aide Memoire

      TEL AVIV, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on the "Investors" page on its website. Q2 2025 Aide Memoire Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicine

      6/26/25 4:30:00 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

      6/26/25 11:44:00 AM ET
      $ADCT
      $CTOR
      $ONCY
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

      TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial results on Wednesday, July 30, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be available within 24 h

      6/25/25 4:30:00 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

      SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

      11/12/24 10:34:14 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Teva Pharmaceutical Industries Limited (Amendment)

      SC 13G/A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

      4/9/24 10:26:26 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

      SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

      2/1/24 8:03:56 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    Financials

    Live finance-specific insights

    See more
    • Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

      TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial results on Wednesday, July 30, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be available within 24 h

      6/25/25 4:30:00 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved

      For an accessible version of this Press Release, please visit www.tevapharm.com On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth consecutive quarter of revenue growth, excluding revenues recorded for Sanofi collaboration.Q1 2025 revenues of $3.9 billion, an increase of 5%; net of $100 million foreign exchange impact, reported revenues growth of 2%.AUSTEDO® – shows continued strong growth, with worldwide revenues of $411 million in Q1 2025, an increase of 39% in local currency terms compared to Q1 2024; increasing 2025 full-year revenue outlook from ~$1.9-2.05 billion to $1.95-2.05 billion.AJOVY® – global revenues of $139 million

      5/7/25 7:00:00 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City

      TEL AVIV, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host Innovation & Strategy Day on Thursday, May 29, 2025 to discuss the acceleration phase of its strategy and portfolio priorities. The event will take place in New York, N.Y. Presentations will begin at 8:30 a.m. Eastern Time and are expected to conclude at 12:30 p.m. Eastern Time. Richard Francis, Teva's President and CEO, along with other members of the executive management team will discuss an update on the strategy and key priorities focusing on growth and innovation. Due to limited capacity, in-person attendance is by invitation only. Analysts a

      5/7/25 7:00:00 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    Leadership Updates

    Live Leadership Updates

    See more
    • The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

      6/26/25 11:44:00 AM ET
      $ADCT
      $CTOR
      $ONCY
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations

      Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company's manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé, who is leaving after 11 years with the Company, including more than four years as Executive Vice President, Global Operations. Mr. Shields will be a member of Teva's Executive Leadership Team and report directly to President and CEO Richard Francis. He will be based in Teva's U.S. headquarters in Parsippany, NJ. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2

      5/15/24 8:15:00 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business

      Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutical Ingredients business (Teva api). Dr. Ananth will lead the API business starting November 27, 2023, and will be based out of Teva's U.S. headquarters in Parsippany, NJ. Richard Francis, Teva's President and CEO said: "I am excited to welcome Ananth back to Teva to lead the Teva api business during this pivotal time for our company, as we continue to progress on our plan for turning Teva api into a standalone business. We're confident that this strategy will result in a more focused end-to-end operation, and I am confident tha

      11/7/23 4:30:00 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care